FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Fate Therapeutics
Gilead Sciences
Allogene Therapeutics
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
AvenCell Therapeutics, Inc.
Incyte Corporation
Regeneron Pharmaceuticals
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Gilead Sciences
Allogene Therapeutics
Genmab
Genmab
Genmab
Genmab
Genmab
Allogene Therapeutics
Allogene Therapeutics
Ossium Health, Inc.
Ossium Health, Inc.
Lyell Immunopharma, Inc.
Novartis
Merck Sharp & Dohme LLC
Seagen Inc.
Celgene
Hoffmann-La Roche
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
AstraZeneca
Celgene
Celgene
Gilead Sciences
Gilead Sciences
Celgene
Gilead Sciences
Sana Biotechnology
Gilead Sciences
Celgene
Acrotech Biopharma Inc.
Gilead Sciences
Sana Biotechnology
Gilead Sciences
Chipscreen Biosciences, Ltd.
Sanofi
Incyte Corporation
Zhejiang Teruisi Pharmaceutical Inc.
Affimed GmbH
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
CStone Pharmaceuticals